Kutatási jelek – Signal Engine

• A Pilot Clinical Trial of Cetuximab Combined With Tislelizumab as Neoadjuvant Therapy for Locally Advanced Oral Squamous Cell Carcinoma — Acute lymphoblastic leukemia
• Severity and management of hypercortisolism in patients with adrenocortical carcinoma and overt Cushing's syndrome. — Adrenocortical carcinoma
• SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN — Myelofibrosis
• Thyroid Cancer: Understanding Risks and Gaining Support - American Oncology Network — Thyroid cancer
• Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy — SCLC
• Inhibitor may turn tumor-protecting immune cells against glioblastoma — Glioblastoma
• Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas — Glioblastoma
• A pilot randomized controlled trial of a multicomponent intervention to improve sexual function in female breast cancer survivors — Breast cancer
• Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells — SCLC
• Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance — Cervical cancer
• Efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma: a retrospective analysis — Head and neck squamous cell carcinoma
• Farnesol disrupts hypoxia-driven EMT signaling in lung cancer spheroids — NSCLC
• Scientists find a new weakness in treatment-resistant prostate cancer — Prostate cancer
• Custom bipolar electrode for bleomycin-based electrochemotherapy in patient-derived uveal melanoma in ovo and ex vivo — Uveal melanoma
• Long‑term metabolic risks after thyroidectomy and thyroid hormone therapy in thyroid cancer survivors: a nationwide cohort study — Thyroid cancer
• Evaluating LLMs in non-metastatic melanoma care: a comparative analysis — Melanoma
• Scientists find breast cancer cells hiding behind protective shields — Breast cancer
• Ovarian cancer proteomic landscape changes across different pathological stages and biomarker‑sets identified with integrative multiomics analysis — Ovarian cancer
• Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation‑eligible hepatocellular carcinoma (EMERALD‑3): a global, randomised, open‑label, sponsor‑blinded, phase 3 study — Hepatocellular carcinoma
• The changing therapeutic landscape of small‑cell lung cancer — SCLC